Clinical Trials Logo

Methylprednisolone clinical trials

View clinical trials related to Methylprednisolone.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06223074 Enrolling by invitation - Methylprednisolone Clinical Trials

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

IN-DXM-EMRR
Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

NCT ID: NCT04979650 Enrolling by invitation - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis

Start date: May 22, 2021
Phase: Phase 2
Study type: Interventional

to determine the rate of asymptomatic gadolinium-enhancing lesions conversion to the non-enhancing black hole (neBHs) with or without corticosteroid pulse therapy in patients with RRMS, and to analyze if treatment of asymptomatic gadolinium enhancement lesions has any effect on the expanded disability status scale. The study is performed in the MS clinic of Bu Ali Sina Hospital in Sari and Mazandaran University of Medical Sciences. 104 recurrent MS patients are admitted based on the admission criteria. They are divided into two groups of intervention and control based on a simple randomization block. The intervention group received 1 gram of methylprednisolone in 500 ccs of normal saline for 5 days and the control group received only 500 ccs of serum. After 6 months, a new MRI is taken from the patients and the possibility of asymptomatic active plaque conversion with or without intervention is compared in the two groups, as well as the amount of EDSS in the two groups. They do not know whether the patient is in the control group or the intervention.